Continued studies from Dr. Aguirre further reveal the advantages of a CBD treatment option for those suffering from seizures.
Noted pediatric neurologist Dr. Carlos G. Aguirre-Velazquez today revealed the positive results of a recent clinical study exploring the efficacy of CBD oil on seizures. The study, which mainly utilized RSHO-X™, the flagship product of HempMeds® Mexico, targeted patients diagnosed with tuberous sclerosis complex (TSC).
“We congratulate Dr. Aguirre for his work in unveiling, like he did in this study, that not only is CBD effective in relieving seizures, but also exhibiting that CBD can be used over long periods of time without harm, compared to antiepileptic or broad-spectrum steroids that can have dangerous side effects if used for several years, including vision and damage to major organs,” said Dr. Stuart Titus, CEO of Medical Marijuana, Inc.
Brief Overview of the Study
Dr. Aguirre’s work primarily measured the reduction in frequency, intensity, and duration of convulsive crises in people with TSC and saw promising results from cannabidiol (CBD) as a treatment for patients with TSC. Also recorded in the study were quality of life, dependence on heavy prescription drugs, and long-term sustainability of treatment with CBD.
The trial comprised patients with varying forms of epilepsy, but the majority in the study have been diagnosed with TSC, a genetic disorder characterized by the growth of noncancerous (benign) tumors in many parts of the body, including the brain, which can lead to convulsive crises. Tumors can lead to significant health problems, especially when they strike organs, especially major ones such as:
Tuberous sclerosis complex also causes developmental problems for those who receive a diagnosis, including autism-like characteristics.
The condition currently affects 1 in 6,000 people and is the leading cause of epilepsy and autism. In total, TSC affects 1 million people worldwide – including 50,000 in the U.S. and 20,000 in Mexico. There is no current cure for TSC, and symptoms of the condition can only be minimized.
Early detection and intervention is critical in treatment of the condition, especially in children. Proper seizure control can help prevent developmental issues and improve learning in children with TSC. Results from Dr. Aguirre’s study showed that 60% of participants who used CBD products saw a clinically significant (80-100%) reduction in the frequency of their seizures.
What Dr. Aguirre’s Study Found
The study concluded, “The experience of parents and patients with medicinal cannabis (CBD), as reported in our survey, suggests that CBD reduced the frequency, intensity, and duration of convulsive crises secondary to TSC.”
Quality of life metrics that were also measured, such mood, appetite, and cognition, saw substantial increases among the patients using CBD – while no serious side effects were reported. Mild effects like drowsiness and increase in appetite were reported early on in the study but were reduced or even disappeared with adjusted doses.
According to Dr. Titus, “Each time new study results are published showing the positive effects of CBD on a new indication, it is a victory for showcasing the therapeutic benefits of CBD and for people around the world suffering from a multitude of debilitating conditions.”
You can discover more about developments from the Medical Marijuana, Inc. portfolio of companies on our news feed. [/vc_column_text][vc_single_image image=”29870″ img_size=”medium” alignment=”center” onclick=”link_image”][/vc_column][/vc_row][vc_row][vc_column][vc_column_text]HempMeds® Mexico’s RSHO-X™
HempMeds® Mexico’s zero-THC product RSHO-X™ became the first-ever cannabis product to receive authorization from the federal government of Mexico, COFEPRIS, for importation into the country when it was approved for young patients suffering from epilepsy. The government of Mexico recently subsidized the full purchase price of RSHO-X™ for patients in the country, further easing access to CBD for those in Mexico who need it most.
Dr. Aguirre presented his findings to an online audience on Thursday, October 12, 2017 on a live event on the Por Grace Facebook. Patients in Mexico looking to access CBD oil can begin the process on the HempMeds® Mexico website.
View the full results of Dr. Aguirre’s study HERE.[/vc_column_text][/vc_column][/vc_row]